Transgenic animal whose expression of the opiate receptors is modified
AssigneeCentre National De La Recherche Scientifique
InventorsBrigitte Kieffer, Hans W. D. Matthes, Frederic Herve Simonin, Andree Dierich, Marianne Lemeur
Life of this patent
Estimating the term…
Abstract
The invention concerns the use of a non-human transgenic mammal whose expression of a gene coding for an opiate receptor is modified, particularly in the nerve tissues with respect to a normal expression, in particular in the nerve tissues, for producing a medicine for the treatment of pathological conditions involving opiate receptors, in particular severe acute or chronic pains, drug addiction or the prevention or the treatment of transplant rejections.
Claims13
A transgenic mouse homozygous for a disruption in the gene encoding the mu type opiate receptor, wherein an exon of said mu type opiate receptor gene is replaced by all or part of a marker gene wherein said disruption in said mouse results in the lack of a functional mu type opiate receptor in said mouse, and said mouse demonstrates no anticociceptive response induced by morphine in any of the nociceptive thresholds, an absence of dependence on morphine after chronic treatment and do not exhibit symptoms of deficiency such as reduced Straub reflex and increased locomotor activity upon withdrawal of administration.
A transgenic mouse homozygous for a disruption in the gene encoding the kappa type opiate receptor, wherein an exon of said kappa type opiate receptor gene is replaced by all or part of a marker gene wherein said disruption in said mouse results in the lack of a functional kappa type opiate receptor in said mouse, and said mouse demonstrates no binding of the kappa selective ligand (3H)CI977 and no analgesia following subcutaneous injection of the selective kappa agonist US0488-H.
A transgenic mouse homozygous for a disruption in the gene encoding the delta type opiate receptor, wherein an exon of said delta type opiate receptor gene is replaced by all or part of a marker gene wherein said disruption in said mouse results in the lack of a functional delta type opiate receptor in said mouse, and said mouse demonstrates no binding of the delta selective ligand naltrindole.
Dependencies are inferred from the claim text.